Carbiotix first European AXOS patent is officially granted
Carbiotix (publ) ("Carbiotix") announces today that the company has received confirmation from the European Patent Office (EPO) that the company’s first AXOS patent has been officially granted. This is an important milestone in securing Carbiotix competitive position as the company accelerates AXOS scale-up activities on the market for prebiotic ingredients, and targets medical food and therapeutic applications.
Carbiotix received confirmation from EPO that the company’s European Patent Application no. 16786855.3, titled: Preparation comprising Arabinoxylo-Oligosaccharides, has been officially granted and will expire in 2036. This is Carbiotix first patent granted in Europe and represents an important milestone to protect the company’s prebiotic ingredient containing AXOS.
Kristofer Cook, CEO for Carbiotix, comments
“The granting of this patent represents a key milestone in securing our competitive position in the European market and provides further confidence as we move quickly forward with the scale-up and commercialisation of our prebiotic ingredient, a corn bran extract containing AXOS. The global market for prebiotic ingredients is valued at close to 5 billion Euros (1), and is a market where we hold a competitive position with a prebiotic ingredient that is according to an internal study up to 10x better than first generation prebiotics however priced the same. This patent also provides protection for our medical food containing AXOS, which is simply a purer form of our AXOS ingredient and where the global market is valued at over 15 billion Euros (2). Even more important, this medical food containing AXOS also serves as backbone for our future therapeutic candidates.”
This information is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the company’s contact person set out below on 9 September 2020.
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.
For further information:
Kristofer Cook, CEO
Tel: +46 708-796580
Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a range of cost-effective gut health testing services and a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics.